Law360, New York (March 05, 2012, 8:19 PM ET) -- Immucor Inc. has agreed to pay $22 million to resolve its part in a class action alleging it conspired with a Johnson & Johnson unit to fix prices of blood-testing reagents, according to a settlement agreement granted preliminary approval Monday.
The settlement resolves claims against Immucor by hospitals and other buyers of reagents, which are used to test blood before transfusions. Immucor also agreed to cooperate in the multidistrict litigation, which will continue in Pennsylvania federal court against Johnson & Johnson subsidiary Ortho-Clinical Diagnostics Inc. over...
Immucor To Pay $22M To Stanch Blood Test Antitrust Action
To view the full article, take a free trial now.
